News
OBI Pharma Enters Exclusive Agreement with MSD for Rights to DIFICID® (fidaxomicin) in Taiwan
OBI Eligible to Receive Milestone Payments as well as US$3.0 …
OBI Pharma to Unblind its Phase 2/3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer by March 2016
TAIPEI, TAIWAN, August 31/ — OBI Pharma, Inc., a Taiwan …
Clarification about the Progressive Disease (PD) number of the OPT-822-001 Clinical Trial as reported in the Taiwan Media on 4 June 2015
There has been a lot of discussion about the Progressive …
OBI Pharma Announces Completion of Patient Enrollment in Phase 2/Phase 3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer
TAIPEI, TAIWAN, July 22/ — OBI Pharma, Inc., a Taiwan …
OBI Pharma, Inc. won Taiwan “Venture Capital Star” The Best Investment Award
The Republic of China Venture Capital Association hosted its “Venture …
OBI Pharma Announces NT$ 1.5 Billion Capital Infusion
OBI Pharma, Inc. (GreTai Securities Market: 4174), announced a new …
OBI Pharma Wins the “Greatest Potential Award” at the 2013 Outstanding Biotech Awards
18 July 2013 – ROC President Ma Ying-jeou attended 2013 …
OBI Pharma re-elects its board of directors and supervisors, and selects a new chairman of the board.
Taipei, Taiwan – 7 February 2013 – OBI Pharma, Inc. …